cjc-1295 / ipamorelin overview.

Growth hormone (GH) secretion is one of the most studied endocrine processes in biomedical research, not because GH is a simple system but precisely because it is not. The hypothalamic-pituitary-hepatic axis governing GH secretion involves at least two distinct stimulatory peptide signals, an inhibitory signal, pulsatile release dynamics, and downstream IGF-1 production with its own feedback loop - all of which make it a rich and complex system for laboratory investigation.

CJC-1295 and ipamorelin are two synthetic research peptides that target distinct receptor pathways within this axis. Each has been independently characterised in published literature. Studied together, they engage the growth hormone secretagogue system through two non-overlapping mechanisms - an experimental design that has made the CJC-1295/ipamorelin combination one of the most frequently referenced dual-compound models in growth hormone axis research.

This overview explains what each compound is, how each mechanism operates at the receptor level, why researchers study them in combination, what the published evidence base looks like, and the research landscape in which they are used. BodyPharm UAE supplies this combination as a lyophilised dual-peptide research compound for laboratory use across the UAE and GCC.

Before examining each compound individually, it is useful to understand the biological system they target. Growth hormone secretion is governed by a three-signal hypothalamic-pituitary axis:

• Growth hormone releasing hormone (GHRH) - a 44-amino acid hypothalamic neuropeptide that stimulates GH synthesis and secretion from somatotroph cells in the anterior pituitary via the GHRH receptor (GHRHR).
• Somatostatin (SRIF) - a hypothalamic inhibitory peptide that suppresses GH secretion. GH pulsatility is largely governed by the alternating dominance of GHRH and somatostatin signals arriving at the anterior pituitary.
• Ghrelin and GHS-R1a agonists - ghrelin is a 28-amino acid peptide secreted primarily from the stomach that acts at the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus. GHS-R1a activation provides a third, distinct stimulatory input into the GH secretion pathway and also modulates somatostatin tone.

Downstream of pituitary GH release, growth hormone acts on the liver to stimulate insulin-like growth factor 1 (IGF-1) production. IGF-1 provides negative feedback to both the hypothalamus and pituitary, and mediates many of the peripheral biological effects attributed to GH in tissue.

Both CJC-1295 and ipamorelin were developed as pharmacological tools to probe specific nodes within this axis. Understanding the distinction between the GHRH receptor pathway and the GHS-R1a pathway is the key to understanding why these two compounds are studied in combination.

Mechanism of Action

CJC-1295 (also known in some literature as DAC:GRF - Drug Affinity Complex Growth Releasing Factor) is a synthetic analogue of native GHRH. Native GHRH (sermorelin is the shortest clinically investigated fragment) has a very short plasma half-life of approximately 7 minutes in circulation, due to rapid proteolytic cleavage primarily by dipeptidyl peptidase IV (DPP-IV) at the N-terminus and by other endopeptidases.

CJC-1295 addresses this limitation through two structural modifications. First, the sequence includes amino acid substitutions that confer resistance to DPP-IV cleavage - the same cleavage site vulnerability that limits native GHRH stability. Second, and more distinctively, CJC-1295 incorporates the Drug Affinity Complex (DAC) modification: a maleimidoproprionic acid (MPA) group appended to the C-terminal lysine residue. This reactive group allows covalent binding to plasma albumin after administration, creating an albumin-bound reservoir that dramatically extends the compound's effective plasma half-life to approximately 6 to 8 days in published pharmacokinetic studies.

Once bound to albumin, CJC-1295 is slowly released in active form, providing sustained GHRH receptor engagement on anterior pituitary somatotroph cells rather than the brief pulse that native GHRH would produce. This sustained engagement is designed to elevate the basal GH secretory tone of the pituitary, though pulsatile release dynamics can still be observed superimposed on this elevated baseline.

Published Clinical Data

CJC-1295 has been evaluated in Phase 1 and Phase 2 human studies. A key publication by Jetté et al. (2005) in the Journal of Clinical Endocrinology & Metabolism characterised the pharmacokinetic and pharmacodynamic profile of CJC-1295 in healthy adult volunteers, documenting dose-dependent increases in mean plasma GH and IGF-1 concentrations sustained over multiple days following a single administration. This study remains the primary human pharmacodynamic dataset for CJC-1295 in the peer-reviewed literature.

Additional Phase 2 work examined CJC-1295 in populations with GH deficiency, providing further pharmacodynamic data in a clinically relevant context. These studies establish CJC-1295 as a pharmacologically characterised GHRH receptor agonist with a validated extended-release mechanism - which is why it serves as a reference compound in growth hormone axis research rather than a purely exploratory tool.

Selectivity Profile

CJC-1295 acts specifically at the GHRH receptor. It does not meaningfully engage other pituitary receptors involved in cortisol, prolactin, or thyroid stimulating hormone secretion at research-relevant concentrations. This selectivity is important for researchers trying to isolate GH/IGF-1 axis effects from broader pituitary confounds.

Structure and Classification

Ipamorelin is a synthetic pentapeptide - five amino acids - with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It was developed by Novo Nordisk A/S and is classified as a growth hormone secretagogue (GHS) that acts as a selective agonist at GHS-R1a, the ghrelin receptor. Its small molecular size relative to CJC-1295 (molecular weight approximately 711 Da versus approximately 3,367 Da for CJC-1295) reflects its origin as an optimised synthetic mimic of the ghrelin signalling motif rather than an analogue of a full-length endogenous peptide.

Mechanism of Action

GHS-R1a is a G-protein coupled receptor (GPCR) - specifically Gq-coupled - expressed on somatotroph cells in the anterior pituitary and also in the hypothalamus. Its endogenous ligand, ghrelin, triggers GH release through a mechanism that is distinct from and additive to the GHRH receptor pathway. Where GHRH receptor activation is primarily cAMP/PKA-mediated (Gs-coupled), GHS-R1a activation operates through the Gq/phospholipase C/IP₃/calcium signalling cascade.

This mechanistic distinction - different receptors, different G-proteins, different intracellular second messenger cascades - is the molecular basis for the synergistic GH release observed in research models when both pathways are engaged simultaneously. The two receptor systems converge at the level of vesicle exocytosis in the somatotroph cell, but through divergent upstream pathways that provide additive rather than redundant stimulation.

Ipamorelin also acts at the hypothalamus to modulate somatostatin tone, providing an additional mechanism through which GHS-R1a agonism can potentiate GH release beyond direct pituitary effects.

Selectivity Advantage

A defining characteristic of ipamorelin that distinguishes it from earlier GHS-R agonists (such as GHRP-6 and GHRP-2) is its high selectivity for GH release relative to other pituitary hormones. Studies have characterised ipamorelin's effects on cortisol (ACTH-mediated), prolactin, and thyroid-stimulating hormone, finding substantially smaller effects on these hormones compared to GH release at equivalent research concentrations.

GHRP-6, an earlier and less selective GHS-R agonist, produces notable cortisol and prolactin release at concentrations that also stimulate GH release - which creates hormonal confounds in experimental settings and limits its utility as a clean GH axis research tool. Ipamorelin's selectivity profile was specifically developed to address this limitation, making it more suitable for experiments in which isolated GHS-R1a-mediated GH release is the research objective.

Research has also noted that ipamorelin does not significantly stimulate appetite pathways at research concentrations in the way that GHRP-6 does - another selectivity advantage relevant to experimental design where behavioural or metabolic confounds need to be minimised.

The combination of CJC-1295 and ipamorelin in research reflects the distinct and complementary receptor mechanisms of each compound. It is not simply a matter of using two compounds that both stimulate GH release - it is that they stimulate GH release through non-overlapping intracellular pathways that are known to produce additive responses when co-activated.

The theoretical and experimental basis for this synergy can be understood as follows:

• CJC-1295 (GHRH receptor / Gs-cAMP pathway): Increases cAMP levels in somatotroph cells, activating protein kinase A, which phosphorylates intracellular targets leading to GH gene transcription and vesicle release. Also increases somatotroph cell sensitivity to subsequent stimulation.
• Ipamorelin (GHS-R1a / Gq-PLC-IP₃-Ca²⁺ pathway): Triggers intracellular calcium release via IP₃, which is a direct trigger for vesicle fusion and GH exocytosis. Also modulates somatostatin inhibitory tone at the hypothalamic level.

When both pathways are engaged, the cAMP-mediated sensitisation from CJC-1295 and the calcium-mediated exocytosis trigger from ipamorelin act in concert on the same somatotroph cell. Published research has characterised the GH release from combined GHRH receptor plus GHS-R1a stimulation as synergistic - greater than the sum of individual compound effects - rather than merely additive. This synergy is the primary scientific rationale for the combined research formulation.

The extended half-life of CJC-1295 also provides a research design consideration: a sustained GHRH receptor signal that can be combined with the shorter-acting ipamorelin at different time points, allowing researchers to explore pulse dynamics and sustained versus pulsatile GH stimulation in the same experimental model.

Researchers using CJC-1295 and ipamorelin in growth hormone axis studies are typically interested in one or more of the following levels of this system:

CJC-1295 and ipamorelin are used in laboratory settings that investigate the following research questions:

• Pituitary biology: Characterising the intracellular signalling cascades in somatotroph cells and how GHRH and GHS-R1a pathways interact at the molecular level.
• GH secretagogue pharmacology: Evaluating the selectivity, potency, and pharmacodynamic profile of synthetic GHS-R agonists, using ipamorelin as a selective reference compound.
• Growth hormone deficiency models: Animal model research investigating GH axis restoration in states of deficiency, using CJC-1295's extended-release mechanism as a sustained stimulation tool.
• Metabolic research: Investigating downstream effects of GH/IGF-1 signalling on lean mass, adipose tissue biology, and insulin sensitivity in preclinical metabolic models.
• Ageing and longevity research: GH secretion declines with advancing age (somatopause). Research into whether GH secretagogue-driven restoration of GH pulsatility in aged animal models affects longevity pathway markers is an active area of investigation.

BodyPharm UAE supplies CJC-1295 and ipamorelin as a lyophilised 10mg/10mg dual-peptide blend in a single vial, available at CJC-1295 / Ipamorelin 20mg. Each batch is independently verified by Janoshik Analytical Laboratory for purity of both peptide components by HPLC and for molecular identity of each compound by mass spectrometry. Batch-specific Certificates of Analysis are provided with every order and are available for review at the product lab results page.

Storage recommendations for lyophilised CJC-1295/ipamorelin material:

• Store unreconstituted lyophilised vials at 2°C to 8°C (refrigerated), protected from light and moisture
• Lyophilised material in this temperature range is stable; avoid freeze-thaw cycling of the lyophilised powder itself
• Reconstituted solution should be used within appropriate stability windows for the buffer system employed and stored refrigerated throughout
• Each vial is supplied with a desiccant-protected seal for transit integrity

Delivery is available same-day across Dubai and Sharjah. Delivery to Abu Dhabi and other UAE emirates carries a maximum 24-hour window. GCC-wide supply (Saudi Arabia, Qatar, Kuwait, Oman, Bahrain) is available with full batch documentation and temperature-protected packaging.

All BodyPharm UAE products are supplied strictly for laboratory and in vitro research purposes only. They are not intended for human or animal consumption, diagnosis, or treatment. Nothing in this article constitutes medical advice. Researchers should comply with all applicable institutional, regulatory, and legal requirements governing the use of research compounds in their jurisdiction.